113 related articles for article (PubMed ID: 7608909)
1. [(Alkylamino)methyl]acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase.
Traxler P; Trinks U; Buchdunger E; Mett H; Meyer T; Müller M; Regenass U; Rösel J; Lydon N
J Med Chem; 1995 Jun; 38(13):2441-8. PubMed ID: 7608909
[TBL] [Abstract][Full Text] [Related]
2. Sulfonylbenzoyl-nitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase.
Traxler PM; Wacker O; Bach HL; Geissler JF; Kump W; Meyer T; Regenass U; Roesel JL; Lydon N
J Med Chem; 1991 Aug; 34(8):2328-37. PubMed ID: 1652014
[TBL] [Abstract][Full Text] [Related]
3. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Regenass U; Lydon NB
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2558-62. PubMed ID: 7708684
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
6. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
[TBL] [Abstract][Full Text] [Related]
7. Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin.
Cassinelli G; Lanzi C; Pensa T; Gambetta RA; Nasini G; Cuccuru G; Cassinis M; Pratesi G; Polizzi D; Tortoreto M; Zunino F
Biochem Pharmacol; 2000 Jun; 59(12):1539-47. PubMed ID: 10799650
[TBL] [Abstract][Full Text] [Related]
8. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors.
Yaish P; Gazit A; Gilon C; Levitzki A
Science; 1988 Nov; 242(4880):933-5. PubMed ID: 3263702
[TBL] [Abstract][Full Text] [Related]
9. Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase.
Trinks U; Buchdunger E; Furet P; Kump W; Mett H; Meyer T; Müller M; Regenass U; Rihs G; Lydon N
J Med Chem; 1994 Apr; 37(7):1015-27. PubMed ID: 8151612
[TBL] [Abstract][Full Text] [Related]
10. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
11. 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity.
Buchdunger E; Trinks U; Mett H; Regenass U; Müller M; Meyer T; McGlynn E; Pinna LA; Traxler P; Lydon NB
Proc Natl Acad Sci U S A; 1994 Mar; 91(6):2334-8. PubMed ID: 8134396
[TBL] [Abstract][Full Text] [Related]
12. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors.
Gazit A; Yaish P; Gilon C; Levitzki A
J Med Chem; 1989 Oct; 32(10):2344-52. PubMed ID: 2552117
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors.
Geissler JF; Traxler P; Regenass U; Murray BJ; Roesel JL; Meyer T; McGlynn E; Storni A; Lydon NB
J Biol Chem; 1990 Dec; 265(36):22255-61. PubMed ID: 2176210
[TBL] [Abstract][Full Text] [Related]
15. BE-23372M, a novel and specific inhibitor for epidermal growth factor receptor kinase.
Tanaka S; Okabe T; Chieda S; Endo K; Kanoh T; Okura A; Yoshida E
Jpn J Cancer Res; 1994 Mar; 85(3):253-9. PubMed ID: 8188523
[TBL] [Abstract][Full Text] [Related]
16. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).
Discafani CM; Carroll ML; Floyd MB; Hollander IJ; Husain Z; Johnson BD; Kitchen D; May MK; Malo MS; Minnick AA; Nilakantan R; Shen R; Wang YF; Wissner A; Greenberger LM
Biochem Pharmacol; 1999 Apr; 57(8):917-25. PubMed ID: 10086326
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the EGF-stimulated cellular proliferation of ER 22 cells by hydroxybiphenyl derivatives.
Million ME; Boiziau J; Parker F; Tocque B; Roques BP; Garbay C
J Med Chem; 1995 Nov; 38(23):4693-703. PubMed ID: 7473597
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice.
Kunkel MW; Hook KE; Howard CT; Przybranowski S; Roberts BJ; Elliott WL; Leopold WR
Invest New Drugs; 1996; 13(4):295-302. PubMed ID: 8824347
[TBL] [Abstract][Full Text] [Related]
19. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines.
Wakeling AE; Barker AJ; Davies DH; Brown DS; Green LR; Cartlidge SA; Woodburn JR
Breast Cancer Res Treat; 1996; 38(1):67-73. PubMed ID: 8825124
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
Naruse I; Ohmori T; Ao Y; Fukumoto H; Kuroki T; Mori M; Saijo N; Nishio K
Int J Cancer; 2002 Mar; 98(2):310-5. PubMed ID: 11857424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
